Ann: Corporate Presentation - ASX Small & Mid-Cap Conference, page-61

First 61 Last

Share
Profile

Follow
syelaw

1,852 Posts.

353

16/09/21

15:38

Post #: 56121927
Share

Originally posted by Psalty: ↑

Seems us 3DP holder remnants are speechless and those that spat the dummy on the way down are winded...

A polished performance by IanO displaying enthusiasm, optimism and confidence in the product and company which has caused buyers to step up and sellers to evaporate. Those who don't know Ian and the company history would tend to think it was all flash and hot air which is so common in financal market circles, whereas we know, he and the team are a bunch of honest, hard working individuals with plenty of skin in the game.
The fact that he confidently talks about the usual $50m ACV target, mentions a potential $500m target and says 3DP is at a moderately priced entry level means that these are realistic targets, not pie-in-the-sky dreams.
He knows that he will be fronting the AGM's and having to answer about these targets and the RAS Media estimate of 90c and I am confident he does not want to be making excuses, rather be saying I told you so, enjoy the ride.

Who knows whether 35c was the bottom of the retracement, all I know is that if it goes below 40c again I'll be topping up some more.

Expand

Did he really mention a 500M target?! wow i never saw that bit, what would that mean for market cap?! Just fantasising and dreaming of course, but market cap wise what do you think we might be looking at?!

Last edited by syelaw: 16/09/21

3DP Price at posting: 49.5¢ Sentiment: Buy Disclosure: Held
7 Upvote

0 Great analysis

Reply

Top Stories

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

There are more pages in this discussion • 41 more messages in this thread...

First 61 Last

Add 3DP (ASX) to my watchlist

(20min delay)
Last 5.3¢		Change -0.002(3.64%)		Mkt cap ! $42.66M

Open	High	Low	Value	Volume
5.2¢	5.5¢	5.2¢	$25.32K	471.7K

Buyers (Bids)

No.	Vol.	Price($)
2	51692	5.3¢

Sellers (Offers)

Price($)	Vol.	No.
5.6¢	1225	1

View Market Depth

No.	Vol.	Price($)
2	51692	0.053
3	635498	0.052
3	508638	0.051
3	122500	0.050
4	151507	0.049

Price($)	Vol.	No.
0.056	1225	1
0.057	218578	2
0.058	300000	2
0.059	500000	1
0.060	102500	2

Last trade - 15.27pm 07/10/2024 (20 minute delay)

3DP (ASX) Chart

Ann: Corporate Presentation - ASX Small & Mid-Cap Conference, page-61

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Corporate Presentation - ASX Small & Mid-Cap Conference, page-61

Top Stories

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News